STAA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ST

Mkt Cap

$1.07B

Volume

502.60K

Next Earnings

November 4th

Loading chart

ST

STAAStaar Surgical Co

STAA

Pay with—

Available Balance0.00

ST

Mkt Cap

$1.12B

Volume

502.60K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Why Staar Surgical Zoomed Almost 8% Higher on TuesdayStaar Surgical stock surged nearly 8% after Stifel analyst Thomas Stephan upgraded the company to 'buy' from 'hold' and raised the price target to $31 from $28. The upgrade was driven by expectations of higher sales in the second half of 2026, particularly for the company's surgically implanted lenses in China, and recognition of Staar's potential as an acquisition target and product developer.The Motley Fool · Sep 29, 2026

Why Staar Surgical Stock Soared TodayStaar Surgical announced a $50 million share buyback program authorized by its board, causing the stock to surge 7.5% on Friday. The company's CEO cited confidence in the business, strong balance sheet, and ample free cash flow, noting that Staar is substantially undervalued. Recent fundamentals support the move, with the company more than doubling net sales year-over-year in Q2, driven by growth in China, and achieving profitability with nearly $149 million in cash.The Motley Fool · Sep 25, 2026

Why Did STAAR Surgical (STAA) Stock Jump 20% After Hours?STAAR Surgical (NASDAQ: STAA) surged 20% in after-hours trading after reporting Q1 2026 preliminary net sales of over $90 million, more than double the $42.6 million from the prior year. Growth was driven primarily by China and the Americas with double-digit expansion, while higher sales and cost streamlining are expected to boost adjusted EBITDA. However, the company faces headwinds in the Middle East, Europe, Africa, and Asia-Pacific due to geopolitical and macroeconomic pressures, and provided no forward guidance citing volatile global conditions.Benzinga · Apr 9, 2026

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory ReviewAlcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65, hitting a new 52-week low.Benzinga · Mar 17, 2026

FDA Expands Approval For Staar Surgical's Popular Implantable LensThe FDA approved an expanded age indication for Staar Surgical's EVO/EVO+ Visian Implantable Collamer Lenses, extending eligibility from ages 21-45 to 21-60 years old. This could add nearly 8 million refractive patients to the market. The approval is based on three-year clinical trial data showing strong safety profiles. Despite the positive news, the stock trades 9.8% below its 20-day moving average with bearish technical indicators, though RSI suggests oversold conditions.Benzinga · Feb 18, 2026

STAAR Surgical Stock Falls After Largest Shareholder Broadwood Gains Board InfluenceSTAAR Surgical shares declined as Broadwood Partners, which owns 31% of the company, gained board influence with two new directors joining alongside Christopher Wang of Yunqi Capital. The changes follow the failed merger with Alcon and include the departure of Chair Elizabeth Yeu, with CEO Stephen Farrell remaining until January 31, 2026. The stock is trading below key moving averages with mixed technical signals.Benzinga · Jan 15, 2026

LASIK Eye Surgery Market Size to Reach USD 3.77 Billion by 2033, Driven by Rising Vision Correction Demand – SNS InsiderThe global LASIK eye surgery market is projected to grow from USD 2.25 billion in 2025 to USD 3.77 billion by 2033, at a CAGR of 6.68%. Growth is driven by rising refractive disorders, AI-enabled surgical innovations, and expanding healthcare infrastructure. However, concerns over long-term safety complications such as corneal thinning and dry eye are limiting adoption. Asia-Pacific is the fastest-growing region, while North America dominates with 44.26% market share.GlobeNewswire Inc. · Jan 14, 2026

Intraocular Lens Market Size to Reach USD 9.85 Billion by 2033, Growing at a CAGR of 6.48% - SNS InsiderThe global intraocular lens market is projected to grow from USD 5.97 billion in 2025 to USD 9.85 billion by 2033, driven by rising cataract prevalence, aging populations, and advanced lens technologies. However, high costs of premium lenses and limited accessibility in developing regions remain key challenges. North America leads the market with 38.61% share, while Asia Pacific is expected to witness the fastest growth at 7.03% CAGR.GlobeNewswire Inc. · Jan 9, 2026

STAAR Surgical Merger With Alcon Fails After Shareholders Vote NoSTAAR Surgical announced that shareholders did not approve its merger with Alcon Inc., which was valued at approximately $1.6 billion. The deal will be terminated with no termination fees owed by either party. STAAR will remain a standalone publicly traded company and focus on profitable growth and expanding its EVO ICL technology globally. Major shareholder Broadwood Partners (30.2% stake) and Yunqi Capital Limited (5.1% stake) had opposed the merger.Benzinga · Jan 6, 2026

STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale ProcessTop investors of STAAR Surgical, including Yunqi Capital and Broadwood Partners, have rejected Alcon's revised acquisition offer of $30.75 per share, citing a flawed sale process and insufficient valuation.Benzinga · Dec 10, 2025

to start trading

ST

STAAStaar Surgical Co

STAA

Pay with—

Available Balance0.00

Your PositionYou don't own any STAA yet.

Related Tickers

Earnings